{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T11:40:02Z","timestamp":1748518802410,"version":"3.41.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jiac-j.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection and Chemotherapy"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.jiac.2025.102696","type":"journal-article","created":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T15:21:16Z","timestamp":1744212076000},"page":"102696","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Can enterobacterales bacteremia with pyelonephritis be treated with ceftriaxone?"],"prefix":"10.1016","volume":"31","author":[{"given":"Yuichi","family":"Shibata","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marisa","family":"Hirose","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiori","family":"Kondo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuhiro","family":"Asai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mao","family":"Hagihara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8876-6411","authenticated-orcid":false,"given":"Hiroshige","family":"Mikamo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jiac.2025.102696_bib1","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1097\/AOG.0b013e318169f6ef","article-title":"ACOG Practice Bulletin No. 91: treatment of urinary tract infections in nonpregnant women","volume":"111","year":"2008","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.jiac.2025.102696_bib2","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/S0140-6736(10)61458-4","article-title":"Burden of endemic health-care-associated infection in developing countries: systematic review and meta-analysis","volume":"377","author":"Allegranzi","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.jiac.2025.102696_bib3","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2014-005099","article-title":"A point prevalence cross-sectional study of healthcare-associated urinary tract infections in six Australian hospitals","volume":"4","author":"Gardner","year":"2014","journal-title":"BMJ Open"},{"key":"10.1016\/j.jiac.2025.102696_bib4","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofac315","article-title":"Epidemiology of complicated urinary tract infections due to Enterobacterales among adult patients presenting in emergency departments across the United States","volume":"9","author":"Lodise","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.jiac.2025.102696_bib5","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1093\/cid\/cis942","article-title":"Community-associated extended-spectrum \u03b2-lactamase\u2013producing Escherichia coli infection in the United States","volume":"56","author":"Doi","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiac.2025.102696_bib6","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1128\/AAC.39.6.1211","article-title":"A functional classification scheme for beta-lactamases and its correlation with molecular structure","volume":"39","author":"Bush","year":"1995","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2025.102696_bib7","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.jiph.2019.09.014","article-title":"Pharmacist recommendations for carbapenem de-escalation in urinary tract infection within an antimicrobial stewardship program","volume":"13","author":"Sadyrbaeva-Dolgova","year":"2020","journal-title":"J Infect Public Health"},{"key":"10.1016\/j.jiac.2025.102696_bib8","doi-asserted-by":"crossref","first-page":"27","DOI":"10.9734\/jpri\/2022\/v34i52B7219","article-title":"A systematic review and meta-analysis of efficacy of carbapenems versus other best available antibiotics in the management of patients with urinary tract infections","author":"Albunayyan","year":"2022","journal-title":"J Pharm Res Int"},{"key":"10.1016\/j.jiac.2025.102696_bib9","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofad500.1817","article-title":"Impact of optimizing urine culture susceptibility reports on prescribing of antimicrobials in outpatients at the Atlanta VA Health Care System (AVAHCS)","volume":"10","author":"Gale","year":"2023","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.jiac.2025.102696_bib10","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1128\/AAC.01009-09","article-title":"Updated functional classification of beta-lactamases","volume":"54","author":"Bush","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2025.102696_bib11","first-page":"149","article-title":"beta-lactam susceptibility of Escherichia coli isolates from urinary tract infections exhibiting different resistance phenotypes","volume":"21","author":"Lerma","year":"2008","journal-title":"Rev Esp Quimioter"},{"key":"10.1016\/j.jiac.2025.102696_bib12","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.jiac.2017.02.002","article-title":"JAID\/JSC guidelines for clinical management of infectious disease 2015 - urinary tract infection\/male genital infection","volume":"23","author":"Yamamoto","year":"2017","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.jiac.2025.102696_bib13","first-page":"17","article-title":"Pharmacokinetic profile of ceftriaxone in man","volume":"77","author":"Patel","year":"1984","journal-title":"Am J Med"},{"key":"10.1016\/j.jiac.2025.102696_bib14","doi-asserted-by":"crossref","first-page":"361","DOI":"10.17305\/bjbms.2018.3544","article-title":"Ceftriaxone treatment of complicated urinary tract infections as a risk factor for enterococcal re-infection and prolonged hospitalization: a 6-year retrospective study","volume":"18","author":"Karlovi\u0107","year":"2018","journal-title":"Bosn J Basic Med Sci"},{"year":"2015","series-title":"Performance standards for antimicrobial susceptibility testing. Twentieth informational supplement. M100eS20","key":"10.1016\/j.jiac.2025.102696_bib15"},{"key":"10.1016\/j.jiac.2025.102696_bib16","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"key":"10.1016\/j.jiac.2025.102696_bib17","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/nrmicro3432","article-title":"Urinary tract infections: epidemiology, mechanisms of infection and treatment options","volume":"13","author":"Flores-Mireles","year":"2015","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.jiac.2025.102696_bib18","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1001\/jama.2016.0287","article-title":"The third international consensus definitions for sepsis and septic shock (Sepsis-3)","volume":"315","author":"Singer","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.jiac.2025.102696_bib19","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1097\/01.CCM.0000202209.42491.38","article-title":"A multicenter, prospective validation of disseminated intravascular coagulation diagnostic criteria for critically ill patients: comparing current criteria","volume":"34","author":"Gando","year":"2006","journal-title":"Crit Care Med"},{"key":"10.1016\/j.jiac.2025.102696_bib20","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.20166","article-title":"Oral \u03b2-lactam antibiotics vs fluoroquinolones or trimethoprim-sulfamethoxazole for definitive treatment of Enterobacterales bacteremia from a urine source","volume":"3","author":"Sutton","year":"2020","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jiac.2025.102696_bib21","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/j.jiac.2024.04.013","article-title":"Retrospective study to investigate appropriate duration of antibiotic treatment for uncomplicated Staphylococcus aureus bacteremia in patients with immunodeficiency","volume":"30","author":"Shibata","year":"2024","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.jiac.2025.102696_bib22","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0191066","article-title":"The clinical impact of bacteremia on outcomes in elderly patients with pyelonephritis or urinary sepsis: a prospective multicenter study","volume":"13","author":"Artero","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.jiac.2025.102696_bib23","doi-asserted-by":"crossref","first-page":"22","DOI":"10.3947\/ic.2017.49.1.22","article-title":"Usefulness of blood cultures and radiologic imaging studies in the management of patients with community-acquired acute pyelonephritis","volume":"49","author":"Kim","year":"2017","journal-title":"Infect Chemother"},{"key":"10.1016\/j.jiac.2025.102696_bib24","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/0732-8893(95)00053-D","article-title":"Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins","volume":"22","author":"Craig","year":"1995","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.jiac.2025.102696_bib25","doi-asserted-by":"crossref","DOI":"10.3390\/pathogens12030417","article-title":"Effective treatments of UTI\u2013is intravesical therapy the future?","volume":"12","author":"Morris","year":"2023","journal-title":"Pathogens"},{"key":"10.1016\/j.jiac.2025.102696_bib26","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1093\/jac\/4.6.580","article-title":"Absence of bioactive metabolites of ampicillin and amoxycillin in man","volume":"4","author":"Cole","year":"1978","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jiac.2025.102696_bib27","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1128\/am.17.3.457-461.1969","article-title":"In vitro antimicrobial activity and human pharmacology of cephalexin, a new orally absorbed cephalosporin C Antibiotic","volume":"17","author":"Thornhill","year":"1969","journal-title":"Appl Microbiol"},{"key":"10.1016\/j.jiac.2025.102696_bib28","doi-asserted-by":"crossref","first-page":"434","DOI":"10.2165\/00003088-199019060-00003","article-title":"Clinical pharmacokinetics of ciprofloxacin","volume":"19","author":"Vance-Bryan","year":"1990","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.jiac.2025.102696_bib29","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2165\/00003088-199732020-00002","article-title":"The clinical pharmacokinetics of levofloxacin","volume":"32","author":"Fish","year":"1997","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.jiac.2025.102696_bib30","first-page":"605","article-title":"[Clinical and pharmacokinetics studies of ceftriaxone upon 2g once daily administration in respiratory tract infections]","volume":"44","author":"Ishioka","year":"1991","journal-title":"Jpn J Antibiot"},{"key":"10.1016\/j.jiac.2025.102696_bib31","first-page":"83","article-title":"Pharmacokinetics of beta-lactam antibiotics","volume":"42","author":"Bergan","year":"1984","journal-title":"Scand J Infect Dis Suppl"},{"key":"10.1016\/j.jiac.2025.102696_bib32","article-title":"\u03b2-Lactam Dosing in Critical Patients: a narrative review of optimal efficacy and the prevention of resistance and toxicity","volume":"11","author":"Pereira","year":"2022","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.jiac.2025.102696_bib33","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1038\/clpt.1981.90","article-title":"Effects of concentration-dependent plasma protein binding on ceftriaxone kinetics","volume":"29","author":"Stoeckel","year":"1981","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jiac.2025.102696_bib34","first-page":"159","article-title":"[Clinical efficacy of ceftriaxone administered once daily against pyelonephritis]","volume":"35","author":"Suzuki","year":"1989","journal-title":"Hinyokika Kiyo"},{"key":"10.1016\/j.jiac.2025.102696_bib35","doi-asserted-by":"crossref","DOI":"10.1002\/j.1875-9114.1993.tb02717.x","article-title":"Urinary tract infections in the elderly","volume":"13","author":"McCue","year":"1993","journal-title":"Pharmacotherapy"}],"container-title":["Journal of Infection and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X25000935?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X25000935?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T11:16:50Z","timestamp":1748517410000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1341321X25000935"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":35,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S1341321X25000935"],"URL":"https:\/\/doi.org\/10.1016\/j.jiac.2025.102696","relation":{},"ISSN":["1341-321X"],"issn-type":[{"type":"print","value":"1341-321X"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Can enterobacterales bacteremia with pyelonephritis be treated with ceftriaxone?","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection and Chemotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jiac.2025.102696","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Japanese Society of Chemotherapy, Japanese Association for Infectious Diseases, and Japanese Society for Infection Prevention and Control. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102696"}}